SRINIVAS AKKARAJU, a director at $MLYS, bought 588,235 shares of the company on 09-04-2025 for an estimated $14,999,992. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately inf%. Following this trade, they now own 588,235 shares of this class of $MLYS stock.
$MLYS Insider Trading Activity
$MLYS insiders have traded $MLYS stock on the open market 23 times in the past 6 months. Of those trades, 6 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 2 purchases buying 2,472,766 shares for an estimated $47,499,981 and 0 sales.
- SRINIVAS AKKARAJU has made 2 purchases buying 1,188,235 shares for an estimated $23,099,992 and 0 sales.
- BIOCAPITAL GP, LLC SAMSARA purchased 600,000 shares for an estimated $8,100,000
- BRIAN TAYLOR SLINGSBY purchased 259,259 shares for an estimated $3,499,996
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 9 sales selling 112,600 shares for an estimated $1,696,764.
- ADAM SCOTT LEVY (CFO and Secretary) has made 0 purchases and 6 sales selling 95,193 shares for an estimated $1,362,615.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 2 sales selling 31,203 shares for an estimated $417,233.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLYS Hedge Fund Activity
We have seen 118 institutional investors add shares of $MLYS stock to their portfolio, and 64 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 2,899,020 shares (+inf%) to their portfolio in Q2 2025, for an estimated $39,223,740
- TCG CROSSOVER MANAGEMENT, LLC removed 2,470,265 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $33,422,685
- ADAMS STREET PARTNERS LLC removed 1,129,807 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $17,941,335
- STATE STREET CORP added 923,379 shares (+177.5%) to their portfolio in Q2 2025, for an estimated $12,493,317
- ORBIMED ADVISORS LLC added 760,351 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,287,549
- JENNISON ASSOCIATES LLC removed 743,711 shares (-37.6%) from their portfolio in Q2 2025, for an estimated $10,062,409
- BLACKROCK, INC. added 647,733 shares (+26.4%) to their portfolio in Q2 2025, for an estimated $8,763,827
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MLYS Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- B of A Securities issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for $MLYS, check out Quiver Quantitative's $MLYS forecast page.
$MLYS Price Targets
Multiple analysts have issued price targets for $MLYS recently. We have seen 3 analysts offer price targets for $MLYS in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $42.0 on 09/08/2025
- Dennis Ding from Jefferies set a target price of $26.0 on 09/03/2025
- Greg Harrison from B of A Securities set a target price of $43.0 on 08/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
